Anticancer Activity in Heterocyclic Organic Structures

Name: Anticancer Activity in Heterocyclic Organic Structures
Brand: Taylor & Francis
Price: 312.4 AUD
Availability: PreOrder

A Pathway to Novel Drug Development Part 1

By: Larbi El Mchichi, Mohammed Bouachrine, Tahar Lakhlifi

Write A Review

eText | 23 December 2025 | Edition Number 1

At a Glance

Format
ePUB

eText

$312.40

or 4 interest-free payments of $78.10 with

Available: 23rd December 2025

Preorder. Online access available after release.

Why choose an eTextbook?

Instant Access *

Purchase and read your book immediately

Read Aloud

Listen and follow along as Bookshelf reads to you

Study Tools

Built-in study tools like highlights and more

* eTextbooks are not downloadable to your eReader or an app and can be accessed via web browsers only. You must be connected to the internet and have no technical issues with your device or browser that could prevent the eTextbook from operating.

This new volume in New Directions in Organic & Biological Chemistry, explores the development of cancer therapeutics, focusing on molecular chemistry and advanced drug design approaches. Written by experts in theoretical chemistry and molecular chemistry, they bridge the gap between theoretical chemistry, molecular biology, and drug development. In Part I, they focus on the fundamental properties of heterocyclic compounds and innovative methodologies being employed to enhance therapeutic potential. By exploring various classes of heterocyclic compounds and diverse anticancer mechanisms, this book provides a valuable resource for researchers, pharmaceutical scientists, and oncologists.

Provides an overview of computational approaches used in drug discovery, including molecular docking, QSAR, and virtual screening
Focuses on the theoretical and practical aspects of these techniques, with applications across various therapeutic areas, including cancer
Addresses the challenges in translating scientific research into effective treatments, offering insights into overcoming common obstacles in the development process
These compounds represent a significant opportunity for the pharmaceutical industry to provide more effective and tailored cancer treatments, further driving market growth
The breadth of the market for heterocyclic anticancer agents is vast and continues to expand as scientific advancements uncover new therapeutic targets